{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:50:04Z","timestamp":1782377404411,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Homologous recombination (HR) deficiency (HRD) is prevalent in ovarian, prostate, and specific subgroups of breast cancer, particularly triple-negative breast cancer (TNBC). Tumor HRD status can be inferred through DNA-based, RNA-based, functional, or image-based approaches. A comprehensive evaluation of the concordance and discordance among HRD prediction methods derived from these different data modalities has been lacking. In the present study, we systematically compared HRD classifications generated by seven distinct methods within a population-representative early-stage TNBC multi-omics cohort and contrasted them to an FDA-approved assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 235 patients from a reported population-based TNBC cohort from southern Sweden profiled by RNA-sequencing, whole genome sequencing, and with available RAD51 foci staining on tissue microarrays and digital whole slide H&amp;E images were included. Seven different HRD classification methods were applied to available data, including sequencing-based (HRDetect and Classifier of HOmologous Recombination Deficiency, CHORD), copy number-based (scarHRD, and copy number signature 17), functional HR (RAD51-FFPE), mRNA-based, and image-based (DeepHRD) methods. Eighteen selected tumors were analyzed with the Myriad myChoice CDx assay for exploratory comparison. Survival analysis was performed using invasive disease-free survival as clinical endpoint in patients treated with adjuvant standard-of-care chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, our results revealed substantial concordance across HRD assessment methods, alongside method-specific discordances attributable to differences in data preprocessing and, importantly, to training strategies that insufficiently account for the well-established clinical and molecular heterogeneity within breast cancer. Sequencing-based methods and scarHRD showed the greatest classification agreement, with discordance to some extent explained by aspects of inadequate tumor cell content, sequencing depth, and fundamental data processing steps (like segmentation). Discordance in mRNA- and image-based classifications appeared associated with molecular subtype features, suggesting that training cohort context may impact performance by incorporating signals (e.g., mRNA expression patterns) that are not specific to HRD status. Despite variation in HRD classification agreement, all seven methods displayed approximately similar prognostic performance in the subset of patients treated with adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, our findings underscore the necessity for rigorous optimization of data processing workflows and threshold definitions to ensure consistency, comparability, and reproducibility across HRD classification platforms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02325-5","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:25:09Z","timestamp":1782368709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Deborah F.","family":"Nacer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Veerla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki","family":"Sasiain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"H\u00e4kkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vallon-Christersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Nik-Zainal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Edsj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Staaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2325_CR1","first-page":"678","volume":"13","author":"XL Du","year":"2023","unstructured":"Du XL, Li Z. Incidence trends in triple-negative breast cancer among women in the United States from 2010 to 2019 by race\/ethnicity, age and tumor stage. Am J Cancer Res. 2023;13:678\u201391.","journal-title":"Am J Cancer Res"},{"key":"2325_CR2","doi-asserted-by":"crossref","unstructured":"Boyle P: Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012, 23 Suppl 6:vi7\u201312.","DOI":"10.1093\/annonc\/mds187"},{"key":"2325_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/his.14784","volume":"82","author":"JY Tsang","year":"2023","unstructured":"Tsang JY, Tse GM. Update on triple-negative breast cancers\u2014highlighting subtyping update and treatment implication. Histopathology. 2023;82:17\u201335.","journal-title":"Histopathology"},{"key":"2325_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41571-018-0001-7","volume":"15","author":"F Pareja","year":"2018","unstructured":"Pareja F, Reis-Filho JS. Triple-negative breast cancers - a panoply of cancer types. Nat Rev Clin Oncol. 2018;15:347\u20138.","journal-title":"Nat Rev Clin Oncol"},{"key":"2325_CR5","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41591-019-0582-4","volume":"25","author":"J Staaf","year":"2019","unstructured":"Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reutersward C, Hakkinen J, et al. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med. 2019;25:1526\u201333.","journal-title":"Nat Med"},{"key":"2325_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517\u201325.","journal-title":"Nat Med"},{"key":"2325_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354.","journal-title":"Nature"},{"key":"2325_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S1470-2045(25)00400-0","volume":"26","author":"D Black","year":"2025","unstructured":"Black D, Davies HR, Koh GCC, Chmelova L, Cubric M, Chalivelaki Chan G, et al. Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis. Lancet Oncol. 2025;26:1417\u201331.","journal-title":"Lancet Oncol"},{"key":"2325_CR9","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1158\/1078-0432.CCR-17-1941","volume":"23","author":"EY Zhao","year":"2017","unstructured":"Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, et al. Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clin Cancer Res. 2017;23:7521\u201330.","journal-title":"Clin Cancer Res"},{"key":"2325_CR10","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","volume":"11","author":"N Chopra","year":"2020","unstructured":"Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun. 2020;11:2662.","journal-title":"Nat Commun"},{"key":"2325_CR11","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764\u201373.","journal-title":"Clin Cancer Res"},{"key":"2325_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","volume":"151","author":"VG Kaklamani","year":"2015","unstructured":"Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015;151:629\u201338.","journal-title":"Breast Cancer Res Treat"},{"key":"2325_CR13","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","volume":"29","author":"S Loibl","year":"2018","unstructured":"Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, et al. Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29:2341\u20137.","journal-title":"Ann Oncol"},{"key":"2325_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"2325_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636\u201348.","journal-title":"Lancet Oncol"},{"key":"2325_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist. 2022;27:167\u201374.","journal-title":"Oncologist"},{"key":"2325_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100049","volume":"36","author":"KD Doig","year":"2023","unstructured":"Doig KD, Fellowes AP, Fox SB. Homologous recombination repair deficiency: an overview for pathologists. Mod Pathol. 2023;36:100049.","journal-title":"Mod Pathol"},{"issue":"1","key":"2325_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F, et al. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. npj Breast Cancer. 2018;4(1):16.","journal-title":"npj Breast Cancer"},{"key":"2325_CR19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","volume":"606","author":"CD Steele","year":"2022","unstructured":"Steele CD, Abbasi A, Islam SMA, Bowes AL, Khandekar A, Haase K, et al. Signatures of copy number alterations in human cancer. Nature. 2022;606:984\u201391.","journal-title":"Nature"},{"key":"2325_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41586-022-04789-9","volume":"606","author":"RM Drews","year":"2022","unstructured":"Drews RM, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, et al. A pan-cancer compendium of chromosomal instability. Nature. 2022;606:976\u201383.","journal-title":"Nature"},{"key":"2325_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/bcr3670","volume":"16","author":"JA Watkins","year":"2014","unstructured":"Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16:211.","journal-title":"Breast Cancer Res"},{"key":"2325_CR22","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen L. J WMM, Van Hoeck A, Cuppen E: Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11:5584.","journal-title":"Nat Commun"},{"key":"2325_CR23","doi-asserted-by":"crossref","unstructured":"Zhu R, Eason K, Chin SF, Edwards PAW, Manzano Garcia R, Moulange R, et al: Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data. Mol Oncol 2025.","DOI":"10.2139\/ssrn.4904689"},{"key":"2325_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-019-0390-2","volume":"51","author":"DC Gulhan","year":"2019","unstructured":"Gulhan DC, Lee JJ, Melloni GEM, Cortes-Ciriano I, Park PJ. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat Genet. 2019;51:912\u20139.","journal-title":"Nat Genet"},{"key":"2325_CR25","doi-asserted-by":"crossref","unstructured":"Liu R, Roberts E, Parsons HA, Stover EH, Choudhury AD, Rhoades J, et al: DirectHRD enables sensitive scar-based classification of homologous recombination deficiency. Nucleic Acids Res 2025, 53.","DOI":"10.1093\/nar\/gkaf313"},{"key":"2325_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41523-024-00671-1","volume":"10","author":"JW Pan","year":"2024","unstructured":"Pan JW, Tan ZC, Ng PS, Zabidi MMA, Nur Fatin P, Teo JY, et al. Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer. NPJ Breast Cancer. 2024;10:60.","journal-title":"NPJ Breast Cancer"},{"key":"2325_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13073-023-01239-7","volume":"15","author":"DH Jacobson","year":"2023","unstructured":"Jacobson DH, Pan S, Fisher J, Secrier M. Multi-scale characterisation of homologous recombination deficiency in breast cancer. Genome Med. 2023;15:90.","journal-title":"Genome Med"},{"key":"2325_CR28","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1200\/JCO.23.02641","volume":"42","author":"EN Bergstrom","year":"2024","unstructured":"Bergstrom EN, Abbasi A, Diaz-Gay M, Galland L, Ladoire S, Lippman SM, et al. Deep learning artificial intelligence predicts homologous recombination deficiency and platinum response from histologic slides. J Clin Oncol. 2024;42:3550\u201360.","journal-title":"J Clin Oncol"},{"key":"2325_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12967-025-06234-7","volume":"23","author":"K Zhang","year":"2025","unstructured":"Zhang K, Qiu Y, Feng S, Yin H, Liu Q, Zhu Y, et al. Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images. J Transl Med. 2025;23:267.","journal-title":"J Transl Med"},{"key":"2325_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115199","volume":"216","author":"F Marme","year":"2025","unstructured":"Marme F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, et al. Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides. Eur J Cancer. 2025;216:115199.","journal-title":"Eur J Cancer"},{"key":"2325_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12915-024-02022-9","volume":"22","author":"CML Loeffler","year":"2024","unstructured":"Loeffler CML, El Nahhas OSM, Muti HS, Carrero ZI, Seibel T, van Treeck M, et al. Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types. BMC Biol. 2024;22:225.","journal-title":"BMC Biol"},{"key":"2325_CR32","doi-asserted-by":"crossref","unstructured":"van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, et al: The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. Cancers (Basel) 2021, 13.","DOI":"10.3390\/cancers13122994"},{"key":"2325_CR33","doi-asserted-by":"crossref","unstructured":"Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutierrez-Enriquez S, Ducy M, Ibrahim YH, et al: A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 2018, 10.","DOI":"10.15252\/emmm.201809172"},{"key":"2325_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00483","volume":"8","author":"LM Korsholm","year":"2024","unstructured":"Korsholm LM, Kjeldsen M, Perino L, Mariani L, Nyvang GB, Kristensen E, et al. Combining homologous recombination-deficient testing and functional RAD51 analysis enhances the prediction of poly(ADP-Ribose) polymerase inhibitor sensitivity. JCO Precis Oncol. 2024;8:e2300483.","journal-title":"JCO Precis Oncol"},{"key":"2325_CR35","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/gcc.22921","volume":"60","author":"RMM Ali","year":"2021","unstructured":"Ali RMM, McIntosh SA, Savage KI. Homologous recombination deficiency in breast cancer: implications for risk, cancer development, and therapy. Genes Chromosomes Cancer. 2021;60:358\u201372.","journal-title":"Genes Chromosomes Cancer"},{"key":"2325_CR36","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606\u201322.","journal-title":"Ann Oncol"},{"key":"2325_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D'Andrea","year":"2018","unstructured":"D\u2019Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172\u20136.","journal-title":"DNA Repair (Amst)"},{"key":"2325_CR38","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","volume":"35","author":"EL Christie","year":"2017","unstructured":"Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35:1274\u201380.","journal-title":"J Clin Oncol"},{"key":"2325_CR39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160\u20137.","journal-title":"J Clin Oncol"},{"key":"2325_CR40","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"2325_CR41","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/s41467-025-58158-x","volume":"16","author":"M Aine","year":"2025","unstructured":"Aine M, Nacer DF, Arbajian E, Veerla S, Karlsson A, Hakkinen J, et al. The DNA methylation landscape of primary triple-negative breast cancer. Nat Commun. 2025;16:3041.","journal-title":"Nat Commun"},{"issue":"428\u2013440","key":"2325_CR42","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(428\u2013440):e425.","journal-title":"Cancer Cell"},{"key":"2325_CR43","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688\u201398.","journal-title":"Clin Cancer Res"},{"key":"2325_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s43856-026-01385-0","volume":"6","author":"HR Davies","year":"2026","unstructured":"Davies HR, Black D, Kvist A, Sigurjonsdottir K, Bosch A, Bowden R, et al. Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer. Commun Med (Lond). 2026;6:118.","journal-title":"Commun Med (Lond)"},{"key":"2325_CR45","doi-asserted-by":"publisher","first-page":"16910","DOI":"10.1073\/pnas.1009843107","volume":"107","author":"P Van Loo","year":"2010","unstructured":"Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A. 2010;107:16910\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2325_CR46","doi-asserted-by":"crossref","unstructured":"Kramer CJH, van Wijk LM, Ruano D, Gelpke-Vermeulen S, van der Tuin K, van der Stoep N, et al: Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond. Br J Cancer 2025.","DOI":"10.1038\/s41416-025-03134-x"},{"key":"2325_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3236","volume":"14","author":"E Fredlund","year":"2012","unstructured":"Fredlund E, Staaf J, Rantala JK, Kallioniemi O, Borg A, Ringner. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res. 2012;14:R113.","journal-title":"Breast Cancer Res"},{"key":"2325_CR48","doi-asserted-by":"crossref","unstructured":"Metovic J, Borella F, D'Alonzo M, Biglia N, Mangherini L, Tampieri C, et al: FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact. Cancers (Basel) 2022, 14.","DOI":"10.3390\/cancers14194699"},{"key":"2325_CR49","doi-asserted-by":"crossref","unstructured":"Igarashi T, Yano K, Endo S, Shiotani B: Tolerance of Oncogene-Induced Replication Stress: A Fuel for Genomic Instability. Cancers (Basel) 2024, 16.","DOI":"10.3390\/cancers16203507"},{"key":"2325_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yexcr.2014.09.030","volume":"329","author":"A Mazouzi","year":"2014","unstructured":"Mazouzi A, Velimezi G, Loizou JI. DNA replication stress: causes, resolution and disease. Exp Cell Res. 2014;329:85\u201393.","journal-title":"Exp Cell Res"},{"key":"2325_CR51","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41388-021-02162-0","volume":"41","author":"S Guerrero Llobet","year":"2022","unstructured":"Guerrero Llobet S, Bhattacharya A, Everts M, Kok K, van der Vegt B, Fehrmann RSN, et al. An mRNA expression-based signature for oncogene-induced replication-stress. Oncogene. 2022;41:1216\u201324.","journal-title":"Oncogene"},{"key":"2325_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116663","volume":"175","author":"KS Prabhu","year":"2024","unstructured":"Prabhu KS, Kuttikrishnan S, Ahmad N, Habeeba U, Mariyam Z, Suleman M, et al. H2AX: a key player in DNA damage response and a promising target for cancer therapy. Biomed Pharmacother. 2024;175:116663.","journal-title":"Biomed Pharmacother"},{"key":"2325_CR53","doi-asserted-by":"publisher","first-page":"21417","DOI":"10.1038\/s41598-024-72306-1","volume":"14","author":"S Roostee","year":"2024","unstructured":"Roostee S, Ehinger D, Jonsson M, Phung B, Jonsson G, Sjodahl G, et al. Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells. Sci Rep. 2024;14:21417.","journal-title":"Sci Rep"},{"key":"2325_CR54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1158\/1078-0432.CCR-15-0529","volume":"22","author":"M Ringner","year":"2016","unstructured":"Ringner M, Jonsson G, Staaf J. Prognostic and chemotherapy predictive value of gene-expression phenotypes in primary lung adenocarcinoma. Clin Cancer Res. 2016;22:218\u201329.","journal-title":"Clin Cancer Res"},{"key":"2325_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/jnci\/dju357","volume":"107","author":"ER Paquet","year":"2015","unstructured":"Paquet ER, Hallett MT. Absolute assignment of breast cancer intrinsic molecular subtype. J Natl Cancer Inst. 2015;107:357.","journal-title":"J Natl Cancer Inst"},{"key":"2325_CR56","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.annonc.2025.03.006","volume":"36","author":"A Marra","year":"2025","unstructured":"Marra A, Morganti S, Pareja F, Campanella G, Bibeau F, Fuchs T, et al. Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives. Ann Oncol. 2025;36:712\u201325.","journal-title":"Ann Oncol"},{"key":"2325_CR57","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1002\/bjs.10741","volume":"105","author":"L Ryden","year":"2018","unstructured":"Ryden L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, et al. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br J Surg. 2018;105:e158\u201368.","journal-title":"Br J Surg"},{"key":"2325_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13073-015-0131-9","volume":"7","author":"LH Saal","year":"2015","unstructured":"Saal LH, Vallon-Christersson J, Hakkinen J, Hegardt C, Grabau D, Winter C, et al. The Sweden Cancerome analysis network - breast (SCAN-B) initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7:20.","journal-title":"Genome Med"},{"key":"2325_CR59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41523-022-00465-3","volume":"8","author":"J Staaf","year":"2022","unstructured":"Staaf J, Hakkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8:94.","journal-title":"NPJ Breast Cancer"},{"key":"2325_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11:e0157368.","journal-title":"PLoS ONE"},{"key":"2325_CR61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13058-021-01392-0","volume":"23","author":"M Aine","year":"2021","unstructured":"Aine M, Boyaci C, Hartman J, Hakkinen J, Mitra S, Campos AB, et al. Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Res. 2021;23:20.","journal-title":"Breast Cancer Res"},{"key":"2325_CR62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2340\/1651-226X.2024.34139","volume":"63","author":"LM Korsholm","year":"2024","unstructured":"Korsholm LM, Broecker V, Mirza MR, Rossing M. Implementing MyChoice(R) CDx HRD testing for the Nordics: lessons from 2021 to 2023. Acta Oncol. 2024;63:70\u20135.","journal-title":"Acta Oncol"},{"key":"2325_CR63","doi-asserted-by":"crossref","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al: Twelve years of SAMtools and BCFtools. Gigascience 2021, 10.","DOI":"10.1093\/gigascience\/giab008"},{"key":"2325_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-023-07102-y","volume":"202","author":"LM van Wijk","year":"2023","unstructured":"van Wijk LM, Vermeulen S, Ter Haar NT, Kramer CJH, Terlouw D, Vrieling H, et al. Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue. Breast Cancer Res Treat. 2023;202:607\u201316.","journal-title":"Breast Cancer Res Treat"},{"key":"2325_CR65","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1158\/1078-0432.CCR-21-0325","volume":"27","author":"Y Bai","year":"2021","unstructured":"Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, et al. An open-source, automated tumor-infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer. Clin Cancer Res. 2021;27:5557\u201365.","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02325-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02325-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:27:11Z","timestamp":1782376031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02325-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02325-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.N.-Z. holds patents or has submitted applications on clinical algorithms of mutational signatures: HRDetect (PCT\/EP2017\/060294), clinical use of signatures (PCT\/EP2017\/060289) and clinical predictor (PCT\/EP2017\/060298). S.N.-Z. also holds the following patents: MMRDetect (PCT\/EP2022\/057387), rearrangement signature methods (PCT\/EP2017\/060279) and hotspots for chromosomal rearrangements (PCT\/EP2017\/060298). Two further patent filings have been made recently (numbers are pending). All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"115"}}